Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.34 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.34 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | GPR3 | P46089 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4861230 | 0.79 | IMPDH2 (0.34) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL11785225 | 0.70 | ALDH1A1 (0.38) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL8588800 | 0.67 | ALDH1A1 (0.40) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL4466423 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL29547 | 0.67 | AHR (0.37) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1388471 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1388411 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7288684 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL7288961 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2230518 | 0.67 | ALDH1A1 (0.35) | KDM4EGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040092436-A1 | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus of cyclosporins | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 2004-05-13 | — | — | US | disclosed |
| US-6521643-B1 | Prevention and/or treatment of nitric oxide synthasey medi-ated diseases such as adult respiratory distress syndrome, myocarditis, synovitis, septic shock, diabetes, ulcerative colitis, cerebral infarction, osteoarthritis | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-1157022-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-11-28 | — | — | EP | disclosed |
| EP-1067926-A2 | IMMUNOSUPPRESSIVE IMIDAZOLE DERIVATIVES AND THEIR COMBINATION PREPARATIONS WITH TACROLIMUS OR CYCLOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
| WO-2000049015-A1 | PYRIDINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-08-24 | — | — | WO | disclosed |
| WO-1999051215-A2 | IMMUNOSUPPRESSIVE IMIDAZOLE DERIVATIVES AND THEIR COMBINATION PREPARATIONS WITH TACROLIMUS OR CYCLOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-14 | — | — | WO | disclosed |
| EP-0946587-A2 | NEW AMIDE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-06 | — | — | EP | disclosed |
| WO-1998027108-A2 | NEW AMIDE COMPOUNDS AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092436-A1 | Immunosuppressive imidazole derivatives and their combination preparations with tacrolimus of cyclosporins | IL2, ICOS, NOS2 | KDM4E 2704/4885GRIN2D 2358/4885GRIN3B 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.